Clinical Trial Update: The Efficacy and Safety of Arbidol in Reducing the Frequency of AECOPD. [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Arbidol's efficacy and safety in reducing the frequency of acute exacerbations of COPD. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• ARbidol (umifenovir)

Snippet

Sponsor: Shengjing Hospital | Conditions: COPD Patients | Phase 4 | Status: COMPLETED